New research presented at the American College of Cardiology Scientific Session 2025 suggests that lorundrostat, an investigational drug, can effectively lower blood pressure in patients with uncontrolled and resistant hypertension.
A phase 2b study, ADVANCE-HTN, evaluated the efficacy and safety of lorundrostat as add-on therapy to standard treatment for patients who remain hypertensive despite taking two to five medications. In total, 285 patients were enrolled in the US trial, who received either a low dose (50mg) or an escalating dose (up to 100mg) of lorundrostat daily.
After 12 weeks, the study found that those receiving the higher dose had a placebo-adjusted reduction in 24-hour average ambulatory blood pressure of 6.5mmHg, while those on the lower dose had a reduction of 7.9mmHg. Lorundrostat was well-tolerated, with side effects consistent with other similar drugs.
The study’s lead author, Dr. Luke Laffin, noted that lorundrostat has a favorable safety profile and may be beneficial for patients with resistant hypertension. Gina Lundberg, another study author, praised the trial’s diversity, which included 40% women and 53% Black participants, as an important aspect of the research.
The addition of lorundrostat to treatment regimens could provide a valuable new option for managing resistant hypertension, although further monitoring is required due to potential side effects.
Source: https://www.medscape.com/viewarticle/advance-htn-shows-benefit-lorundrostat-resistant-2025a10007km?form=fpf